RxDoctor Payments Data

Victor Nitti, MD

Urology · Los Angeles, CANPI 1003800806

Payments from drug & device makers

$167,685in general payments, 2019–2025

Across 203 payments — averaging $826.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$127K
  • Medtronic$30K
  • Boston Scientific$6K
  • Axonics, Inc.$1K
  • Coloplast$1K
  • Urovant Sciences Inc$1K
  • plus $1K from 9 others

What the payments were for

  • Consulting fees$2,76214%
  • Speaking & faculty fees$2,50013%
  • Grants$1,7289%
  • Travel & lodging$1,0185%
  • Food & beverage$11,22458%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)46$127,162
Medtronic(2 entities)62$29,828
Boston Scientific27$5,702
Axonics, Inc.16$1,363
Coloplast7$1,336
Urovant Sciences Inc4$1,112
C. R. Bard, Inc. & Subsidiaries19$281
Olympus America Inc.2$236
Procept Biorobotics Corporation2$230
Rochester Medical Corporation12$144
Urogen Pharma, Inc.1$135
BD1$63
Teleflex LLC2$42
Urocure LLC1$28
Sumitomo Pharma America, Inc.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$167,685 in reported general payments places this provider in the 90th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$521,621
Medicare patients
704
Services billed
15,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron202$182,500
MyrbetriqMirabegron118$127,451
Solifenacin Succinate96$5,733
Methenamine Hippurate54$5,075
Trospium Chloride63$4,144
Estradiol49$3,139
Tamsulosin Hcl96$1,420
Clindamycin Phosphate28$869
NitrofurantoinNitrofurantoin Macrocrystal14$740
Gentamicin Sulfate14$509
Finasteride51$449
Sodium ChlorideSodium Chloride Irrig Solution20$332
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst27$326
Nystatin18$231
Cephalexin94$195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$24$182,500202 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,324 urology providers in California.

Other urology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →